Emphasizing Biologics Space as Payer Priority
Kareem Karara, PharmD, BCPS, CCHP continues this discussion on unbranded biologics, discussing payer priorities for treatment options.
EP: 1.Overview and Prevalence of Biologics
EP: 2.Defining Unbranded Biologics
EP: 3.Clinical Impacts of Biologics on Patient Quality of Care
EP: 4.Pipeline Development and Future Implications of Unbranded Biologics
EP: 5.Emphasizing Biologics Space as Payer Priority
EP: 6.Evolving Complexity of Biologics Space
EP: 7.Differentiating Between Unbranded Biologics and Biosimilars
EP: 8.The Impact of Unbranded Biologics in the Evolving Treatment Landscape of Autoimmune Disease
EP: 9.Implications of Multiple Switching with Biologic Therapies
EP: 10.Factors Affecting Biologics Affordability for Patient Treatment
EP: 11.Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
Kareem Karara, PharmD, BCPS, CCHP: To define a biologic and how they are different from small-molecule drugs, a biologic is a substance that is derived from a biologic source: human, animal, microorganism. [Biologics] include medications such as antibodies, blood products, and vaccines. Most drugs on the market today are small-molecule compounds that are manufactured through a type of chemical synthesis. The primary difference between those traditional small-molecule medications and biologic medications is that while the small-molecule drugs are chemically derived, biologics are extracted from living organisms.
The biologic space is a priority for payers because biologics represented 70% of the growth in US drug spending between the years 2010 and 2015. Biologics continue to account for the fastest-growing segment of prescription-drug spending in the United States. The global biologics market size was valued at $366 billion in 2021. According to Precedence Research, that global biologics market size is expected to be worth somewhere around $719 billion by the year 2030. So, it continues to grow. A higher share of biologics in the pharmaceutical market and the rising use of those drugs over traditional small-molecule drugs is driving their market expansion. An ever-increasing number of health conditions are also primarily managed with biologics. [These include] diseases like hemophilia, rheumatoid arthritis, chronic migraines, and cancers.
Transcript edited for clarity.
FDA Drafts Rules for Fair Biosimilar Promotion
June 11th 2024An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.
Read More
